美国心脏病学会重磅发布：这两款药物成减肥"黄金标准"！

Core Viewpoint - The American College of Cardiology (ACC) has officially recognized semaglutide and tirzepatide as preferred medications for obesity treatment, marking a significant shift in obesity management strategies [4][7]. Group 1: Breakthrough Therapies - Innovative drugs like semaglutide and tirzepatide not only significantly reduce weight but also provide additional cardiovascular protection for high-risk patients, effectively lowering the risks of cardiovascular death, heart attacks, and strokes [10]. - These medications represent the most effective weight loss solutions currently available, particularly for patients with type 2 diabetes or existing cardiovascular diseases [10]. Group 2: Obesity as a Health Threat - Obesity is highlighted as a critical health risk, contributing to metabolic disorders, respiratory issues, and various heart diseases, and is recognized as an independent risk factor for cardiovascular diseases [11]. - The consensus emphasizes that obesity is not merely an aesthetic issue but a serious health concern that requires urgent attention [11]. Group 3: Weight Loss Thresholds - Research indicates that different degrees of weight loss yield varying cardiovascular benefits: a 10%-15% weight loss can reduce general cardiovascular risks, while heart failure patients may need to lose over 15% for significant improvements [12]. - The treatment options include lifestyle interventions, weight loss surgery, and pharmacotherapy, with the latter being increasingly favored due to its effectiveness and safety [12][13]. Group 4: NuSH Therapy Advantages - NuSH therapy, which includes semaglutide and tirzepatide, is praised for its unique advantages, including targeting appetite regulation and allowing for personalized dosage adjustments to achieve optimal results [19]. - The therapy is seen as a pivotal advancement in obesity treatment, ushering in an era of precision medicine [13]. Group 5: Comparison of Weight Loss Medications - Semaglutide (weekly) leads to an average weight loss of 14.9%, while tirzepatide (weekly) shows the highest efficacy with an average weight loss of 20.9% [18][20]. - Other medications like liraglutide (daily) result in an average weight loss of 8% [18]. Group 6: Long-term Treatment and Challenges - Long-term treatment is crucial, as discontinuation can lead to weight regain; thus, a combination of medication and lifestyle changes is essential for maintaining weight loss [21]. - Current challenges include limited availability and high costs of semaglutide and tirzepatide, which may hinder accessibility for patients [22]. Group 7: Cardiovascular Benefits Beyond Weight Loss - The benefits of NuSH therapy extend beyond weight reduction, with semaglutide reducing the risk of heart attacks and strokes in non-diabetic obese patients, and improving exercise capacity in heart failure patients [23]. - Treatment goals should be individualized, focusing on weight loss of at least 5% to improve metabolic health and 10% for cardiovascular benefits [23].